NV-ESI-GROUP
ESI Group (Paris:ESI), leading innovator in Virtual Prototyping software and services for manufacturing industries, helped Farasis Energy, a Chinese-American battery provider, win in record-breaking time, a call for tenders made by a premium German automotive OEM. Thanks to ESI’s expertise, the reliability of the virtual prototype of the new Farasis battery model was decisive in a “zero real prototype” procedure, stipulating the elimination of any physical prototype.
The move of the automotive industry toward electrification is seemingly unstoppable. Manufacturers are announcing aggressive plans for Electric Vehicle (EV) production, and the International Energy Agency says the number of EVs will grow from 3 to 125 million by 2030. So, it’s no wonder that new players are entering the market, breaking the traditional rules of product design – new players like lithium-ion battery maker Farasis Energy. Looking to collect wins in this fast-growing market, the team at Farasis relied on ESI’s expertise to prove to a major German car maker that they were the best supplier – based solely on a virtual prototype. This collaboration around ESI’s Virtual Performance Solution (VPS) allowed to virtualize and secure the behavior of the battery in vibration or vehicle crash situations.
Dr. Matt Klein, Advanced R&D Director at Farasis Energy, emphasized the key role ESI played in this project: “Half-way through the bidding process, the manufacturer actually decided to remove the physical prototype step – they would make their decision based on the virtual prototype. In just 8 months, we went from limited Virtual Prototyping capability to winning those bids. The head of the whole program conducting the bidding process went out of his way to tell us that the mechanical simulation was an instrumental part in helping us get the design approved. We could not have done that without ESI. Our partnership with ESI is truly strategic in bringing our simulation capabilities to a global leading standard.”
Two fundamental elements differentiated ESI’s VPS in this project:
- The reliability of the results, eliminating the need for a real prototype verification, as a result of the consideration of complex physical phenomenon inside the battery.
- The integration level of different virtual vibration and crash tests in one solution, allowing iteration loops and quick decisions.
Farasis relied on ESI’s proven knowledge of the automotive industry and ability to provide real results, virtually, thanks to virtual prototyping. The capability to build a global model, covering several engineering disciplines, led to a highly efficient workflow and ultimately a cost-effective solution for Farasis.
Since their win, Farasis has opened a new factory on-site in Germany, dedicated to the research & development of their batteries for the German car maker. ESI is now putting in place a platform for Farasis’ international team of simulation engineers, one that is fully automated and customized to their way of working. Thanks to this Platform, the Farasis team will work together – regardless of what continent they are on – with great efficiency and transparency, on common Virtual Prototyping models. And what began as a bi-lateral partnership has quickly evolved into an ecosystem comprised of three major players – Farasis, ESI Group, and the automotive manufacturer – all hungry to tap into the EV market.
About Farasis
Farasis Energy, Inc. created in California in 2002 is a company specialized in the conception and distribution of batteries. Present in China (headquarters), in the Silicon Valley (R&D center), and in Europe, the Group is one of the world leaders in his sector. Farasis’ ambition is to position itself as a pivot to better meet the challenges of its industrial clients: saving time to market and the costs of production while maintaining a high level of reliability and safety.
ESI and Farasis will jointly showcase their expertise and partnership at the CES 2020 in Las Vegas. Meet them in ESI Booth: LVCC, Automotive Section - North Hall, booth #9020
About ESI Group
ESI Group is a leading innovator in Virtual Prototyping software and services. Specialist in material physics, ESI has developed a unique proficiency in helping industrial manufacturers replace physical prototypes by virtual prototypes, allowing them to virtually manufacture, assemble, test and pre-certify their future products. Coupled with the latest technologies, Virtual Prototyping is now anchored in the wider concept of the Product Performance Lifecycle™, which addresses the operational performance of a product during its entire lifecycle, from launch to disposal. The creation of a Hybrid Twin™, leveraging simulation, physics and data analytics, enables manufacturers to deliver smarter and connected products, to predict product performance and to anticipate maintenance needs.
ESI is a French company listed in compartment B of NYSE Euronext Paris. Present in more than 40 countries, and addressing every major industrial sector, ESI Group employs about 1200 high-level specialists around the world and reported annual sales of €139 million in 2018. For more information, please visit www.esi-group.com .
Follow ESI
LinkedIn
Facebook
Twitter
YouTube
View source version on businesswire.com: https://www.businesswire.com/news/home/20200106005895/en/
Contact:
ESI Group Shan Florence Barré press@esi-group.com +33 1 49 78 28 28
Lola Gozlan lola.gozlan@shan.fr +33 6 24 76 83 40
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
